Subject 16’s (ER+/PR+/HER2-) biopsy specimens, which showed significantly increased HER3 expression post systemic therapy initiation, also showed increased signaling in downstream mediators of the PI3K-AKT pathway (Fig. 3C), implicating HER3 as a potential active mechanism of continued cell survival in this cancer. The gene discussed is ESR1; the disease is cancer.